Ramnik Xavier Increases Stake in MoonLake Immunotherapeutics
Ramnik Xavier acquires 22,195 shares of MoonLake Immunotherapeutics.
Key Points
- Ramnik Xavier acquired 22,195 shares of MoonLake Immunotherapeutics on June 17, 2026, with the stock trading at $19.19.
- MoonLake Immunotherapeutics, listed on NasdaqCM, has a market cap of approximately $1.41 billion and a 52-week range of $5.95 to $62.75.
- The company focuses on inflammatory skin and joint disease therapies, led by CEO Dr. Jorge Santos da Silva from its headquarters in Zug, Switzerland.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Ramnik Xavier has increased his stake in MoonLake Immunotherapeutics by acquiring 22,195 shares. This transaction took place on June 17, 2026, with the stock trading around $19.19 on the Nasdaq Capital Market. The filing indicates an insider's belief in the company's potential.
MoonLake Immunotherapeutics Stock Up 49.3%
Shares of NasdaqCM:MLTX traded near $19.19 recently. MoonLake Immunotherapeutics has a market capitalization of about $1.41 billion. The company is not currently profitable, thus it has no meaningful P/E ratio. Its forward P/E is reported at -5.57, reflecting its current lack of earnings. The stock has experienced a wide 52-week range, from a low of $5.95 to a high of $62.75. It has a 50-day moving average of $17.88 and a 200-day moving average of $19.01. The company's financial health is supported by a strong current ratio of 8.60 and a quick ratio of 7.89, with a debt-to-equity ratio of 39.68.
$MLTX stock price
Daily closing prices, year to date. Not investment advice.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland. It focuses on developing treatments for inflammatory skin and joint diseases. The company is working on Sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody, aimed at treating conditions such as hidradenitis suppurativa, psoriatic arthritis, and psoriasis. Founded in 2021, the company is led by CEO Dr. Jorge Santos da Silva and employs around 130 people.
Bottom Line
Ramnik Xavier's recent purchase of MoonLake Immunotherapeutics shares suggests confidence in the company's future. Investors often track insider transactions like this to gauge sentiment. However, it's important to remember that insider transactions are reported after the fact and may not reflect the current position. MoonLake continues to focus on its innovative therapies for inflammatory diseases, making it a company to watch in the biotechnology sector.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.